SAN.PA vs. GSK
Compare and contrast key facts about Sanofi (SAN.PA) and GlaxoSmithKline plc (GSK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: SAN.PA or GSK.
Key characteristics
| SAN.PA | GSK | |
|---|---|---|
| YTD Return | 1.64% | 12.01% |
| 1Y Return | -7.06% | 18.78% |
| 3Y Return (Ann) | 6.05% | 6.82% |
| 5Y Return (Ann) | 7.57% | 4.73% |
| 10Y Return (Ann) | 5.55% | 1.76% |
| Sharpe Ratio | -0.13 | 1.07 |
| Daily Std Dev | 26.04% | 17.76% |
| Max Drawdown | -50.84% | -55.72% |
| Current Drawdown | -12.26% | -6.85% |
Fundamentals
| SAN.PA | GSK | |
|---|---|---|
| Market Cap | €108.46B | $81.21B |
| EPS | €4.30 | $2.99 |
| PE Ratio | 20.21 | 13.29 |
| PEG Ratio | 0.85 | 1.09 |
| Revenue (TTM) | €46.03B | $30.33B |
| Gross Profit (TTM) | €31.70B | $19.92B |
| EBITDA (TTM) | €12.52B | $10.30B |
Correlation
The correlation between SAN.PA and GSK is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
SAN.PA vs. GSK - Performance Comparison
In the year-to-date period, SAN.PA achieves a 1.64% return, which is significantly lower than GSK's 12.01% return. Over the past 10 years, SAN.PA has outperformed GSK with an annualized return of 5.55%, while GSK has yielded a comparatively lower 1.76% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
SAN.PA vs. GSK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SAN.PA) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
SAN.PA vs. GSK - Dividend Comparison
SAN.PA's dividend yield for the trailing twelve months is around 3.90%, more than GSK's 3.54% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
SAN.PA Sanofi | 3.90% | 3.97% | 3.71% | 3.63% | 4.02% | 3.44% | 4.03% | 4.14% | 3.83% | 3.65% | 3.72% | 3.61% |
GSK GlaxoSmithKline plc | 3.54% | 3.75% | 4.72% | 4.93% | 5.53% | 4.35% | 5.53% | 5.80% | 6.89% | 5.94% | 6.18% | 4.49% |
Drawdowns
SAN.PA vs. GSK - Drawdown Comparison
The maximum SAN.PA drawdown since its inception was -50.84%, smaller than the maximum GSK drawdown of -55.72%. Use the drawdown chart below to compare losses from any high point for SAN.PA and GSK. For additional features, visit the drawdowns tool.
Volatility
SAN.PA vs. GSK - Volatility Comparison
Sanofi (SAN.PA) has a higher volatility of 7.48% compared to GlaxoSmithKline plc (GSK) at 4.62%. This indicates that SAN.PA's price experiences larger fluctuations and is considered to be riskier than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
SAN.PA vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities